The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives

OBJECTIVE: Clinical efficacy of cytostatic anticancer agents can be determined with the progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a new treatment (PFS2) to the PFS of the most recent treatment on which the patient has experienced progression (PFS1). Clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Kruis, Nienke, van der Ploeg, Phyllis, Wilting, Jody H.C., Caroline Vos, M., Thijs, Anna M.J., de Hullu, Joanne, Ottevanger, Petronella B., Lok, Christianne, Piek, Jurgen M.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309411/
https://www.ncbi.nlm.nih.gov/pubmed/35898197
http://dx.doi.org/10.1016/j.gore.2022.101035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309411/
https://www.ncbi.nlm.nih.gov/pubmed/35898197
http://dx.doi.org/10.1016/j.gore.2022.101035

Ejemplares similares